ADIPOQ ELISA Kit

Catalog No. ABIN2745424

The Human ADIPOQ ELISA Kit (ABIN2745424) is a Colorimetric ELISA Kit designed to quantify Human ADIPOQ.

Quick Overview for ADIPOQ ELISA Kit (ABIN2745424)

Target: ADIPOQ (Adiponectin (ADIPOQ))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 0.5-32 ng/mL

Application: ELISA

Sample Type: Cell Culture Supernatant, Plasma, Serum, Urine

Product Details ADIPOQ ELISA Kit

Minimum Detection Limit: 0.5 ng/mL

Purpose: The Adiponectin (human) ELISA Kit is to be used for the in vitro quantitative determination of human Adiponectin in serum, plasma, urine and cell culture supernatant.

Analytical Method: Quantitative

Specificity: Detects human adiponectin.

Cross-Reactivity: Human

No Cross-Reactivity: Mouse (Murine), Rat (Rattus)

Cross-Reactivity (Details): Does not cross-react with mouse adiponectin, rat adiponectin, human resistin, human RELM-beta or human leptin.

Sensitivity: 100 pg/mL

Characteristics: Adiponectin (human) ELISA Kit

Application Details

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C

Storage Comment: Short Term Storage: +4°C
Long Term Storage: +4°C
12 months after the day of manufacturing. See expiry date on ELISA Kit box.

Target Details for ADIPOQ

Target: ADIPOQ (Adiponectin (ADIPOQ))

Alternative Name: Adiponectin

Background: Adiponectin [ACRP30, AdipoQ] is a promising biomarker of insulin resistance and type 2 diabetes mellitus (T2DM) but also as a potential target for management of the metabolic syndrome. It is a very robust marker that is not prone to degradation or acute inflammatory challenges, is present in relatively high concentrations in the peripheral circulation, and can be collected by a variety of methods. The benefits of using adiponectin assays in clinical settings include, (a) prediction of risk of diabetes and metabolic status and (b) providing a tool to monitor metabolic improvements. Adiponectin exerts anti-atherogenic and anti-inflammatory properties and may be important as a biomarker for obesity-related cardiovascular disease (CVD). New findings showed urinary adiponectin excretion as an independent new biomarker of microvascular and macrovascular damage in T2DM and suggested it as a very promising tool for early cardiovascular disease risk assessment. Adiponectin serum level was also described as a good biomarker of colorectal adenoma, this being related to the positive correlation between obesity and increased risk of cancer at various sites (colorectal, breast, prostate and endometrium).

UniProt: Q15848